Efepoetin Alfa

Summary

Efepoetin Alfa (CHEMBL4594471) is a phase-3 clinical-stage protein (ATC B03XA10); indicated across 2 conditions including anemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• ATC class: B03XA10
• Indications: 2 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594471
Name	Efepoetin Alfa
Type	Protein
Max phase	3
ATC	B03XA10

Also known as: Efepoetin alfa, Efepoetina alfa, Efepoetine alfa, EFEPOETIN ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anemia	3	MONDO:0002280	EFO:0004272

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06466785	PHASE3	RECRUITING	A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
NCT04155125	PHASE3	COMPLETED	A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient
NCT06490939	PHASE1	COMPLETED	Clinical Trial of Efepoetin Alfa in Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).